Any drug that is known to cause cell cycle mediated apoptosis, ROS generation or NF-κB inhibition without any toxic effects is considered an ideal candidate for combination with cisplatin for treatment of ovarian cancer. This evidence concerns the gene NFKB1 and ovarian cancer.